In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera

BACKGROUND: An important limiting factor in the development of centrally acting pharmaceuticals is the blood-brain barrier (BBB). Transport of therapeutic peptides through this highly protective physiological barrier remains a challenge for peptide drug delivery into the central nervous system (CNS)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Guillemyn, Karel, Kleczkowska, Patrycja, Novoa, Alexandre, Vandormael, Bart, Van den Eynde, Isabelle, Kosson, Piotr, Asim, Muhammad Faheem, Schiller, Peter W, Spetea, Mariana, Lipkowski, Andrzej W, Tourwé, Dirk, Ballet, Steven
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2012
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3284447/
https://ncbi.nlm.nih.gov/pubmed/22289619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-6606-5-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge